SHREWSBURY STEPHEN B 4

4 · IMPEL NEUROPHARMA INC · Filed Sep 22, 2021

Form 4

Period: 2021-09-21

Chief Medical Officer

Transactions

Exercise/Conversion
Stock Option (right to buy)
2021-09-21−14,780→ 0 total
Exercise: $1.97Exp: 2027-10-17→ Common Stock (14,780 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-09-21−53,954→ 29,587 total
Exercise: $2.95Exp: 2029-02-07→ Common Stock (53,954 underlying)
Exercise/Conversion
Common Stock
2021-09-21$1.97/sh+14,780$29,117→ 14,780 total
Exercise/Conversion
Common Stock
2021-09-21$2.46/sh+4,650$11,439→ 19,430 total
Exercise/Conversion
Stock Option (right to buy)
2021-09-21−4,650→ 541 total
Exercise: $2.46Exp: 2028-03-08→ Common Stock (4,650 underlying)
Exercise/Conversion
Common Stock
2021-09-21$2.95/sh+53,954$159,164→ 73,384 total

Footnotes (3)

[F1]The option is 100% vested and exercisable.
[F2]The option vested as to 25% of the total shares on February 13, 2019, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on February 13, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.
[F3]The option vested as to 25% of the total shares on February 8, 2020, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on February 8, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

Documents

1 file